Appointment of Joint Corporate Broker

RNS Number : 8822B

MaxCyte, Inc.

12 June 2019

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Appointment of Joint Corporate Broker

Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage, cell-based therapies and life sciences company, announces the appointment of Numis as the Company's joint Corporate Broker with immediate effect. Panmure Gordon will continue to act as the Company's Nominated Adviser and joint Corporate Broker.

About MaxCyte 

MaxCyte is a global clinical-stage cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based therapy to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250m plus significant additional potential milestones from the multi-drug commercial agreement with Kite announced 1 March 2019. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	[phone]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns	[phone]
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji --------------------------------------------------------------	[phone] [e-mail]

 

END

 

 

APPFBMFTMBABBAL